A cell-based assay for IκBα stabilization using a two-color dual luciferase-based sensor

Assay and Drug Development Technologies

Volumn 5, Issue 1, 2007, Pages 85-103

  Davis, R Eric ^a   Zhang, Ya Qin ^b   Southall, Noel ^b   Staudt, Louis M ^a   Austin, Christopher P ^b   Inglese, James ^b   Auld, Douglas S ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXYCYCLINE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PROTEASOME INHIBITOR;

ARTICLE; ASSAY; CONCENTRATION RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SENSOR;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; HUMANS; I-KAPPA B PROTEINS; LUCIFERASES; LYMPHOMA, B-CELL; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34147214417     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.048     Document Type: Article

References (29)

1. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB sys tem: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
2. Burke JR: Targeting IκB kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Dev 2003;6:720-728.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
4. Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;184:1861-1874.
5. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al.: Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
6. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al.: A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-110.
7. Coish PDG, Wickens PL, Lowinger TB: Small molecule inhibitors of IKK kinase activity. Expert Opin Ther Patents 2006;16:1-12.
8. Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, et al.: MALT1- and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005;105:2891-2899.
9. Li X, Fang Y, Zhao X, Jiang X, Duong T, Kain SR: Characterization of NκFB activation by detection of green fluorescent protein-tagged IκB degradation in living cells. J Biol Chem 1999;274:21244-21250.
10. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
11. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, et al.: Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003;4:609-615.
12. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al.: Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006;103:11473-11478.
13. Niles WD, Coassin PJ: Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. Assays Drug Dev Technol 2005;3:189-202.
14. Cleveland PH, Koutz PJ: Nanoliter dispensing for uHTS using pin tools. Assay Drug Dev Technol 2005;3:213-225.
15. Mainquist, JKD, Robert C, Weselak MR, Meyer AJ, Burow KM, Sipes DG, et al.: inventors; IRM LLC, assignee: Specimen plate lid and method of using. US Patent 6534014. Issue date March 18, 2003.
16. Almond B, Hawkins E, Stecha P, Garvin D, Paguio A, Butler B, et al.: Introducing Chroma-Luc technology. Promega Notes 2003;85:11-14.
17. Branchinia BR, Southworth TL, Khattak NF, Michelini E, Roda A: Red- and green-emitting firefly luciferase mutants for bioluminescent reporter applications. Anal Biochem 2005;345:140-148.
18. Zhao HF, Kiyota T, Chowdhury S, Purisima E, Banville D, Konishi Y, Shen SH: A mammalian genetic system to screen for small molecules capable of disrupting protein-protein interactions. Anal Chem 2004;76:2922-2927.
19. Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, Garbison KE, et al.: The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration- response assays and estimation by replicate-experiment studies. J Biomol Screen 2006;11:253-261.
20. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, et al.: Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-κB in malignant melanoma cells. Am J Physiol Cell Physiol 2001;280:C659-C676.
21. Shimohashi N, Nakamuta M, Uchimura K, Suginoto R, Iwamoto H, Enjoji M, et al.: Selenoorganic compound Ebselen, inhibits nitric oxide and tumor necrosis factor-α production by the modulation of Jun-N-terminal kinase and the NFκB signaling pathway in rat Kupffer cells. J Cell Biochem 2000;78:595-606.
22. Park JB: Concurrent measurements of promoter activity and transfection efficiency using a new reporter vector containing both Photinus pyralis and Renilla reniformis luciferase genes. Anal Biochem 2001;291:162-166.
23. Gammon ST, Leevy WM, Gross S, Gokel GW, Piwnica-Worms D: Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. Anal Chem 2006;78:1520-1527.
24. Smoak KA, Cidlowski JA: Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004;125:697-706.
25. Aljada A, Ghanim H, Assian E, Mohanty P, Hamouda W, Garg R, et al.: Increased IκB expression and diminished nuclear NF-κB in human mononuclear cells following hydrocortisone injection. J Clin Endocrinol Metab 1996;84: 3386-3389.
26. Löwenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, et al.: Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 2005;106:1703-1710.
27. Nelson G, Wilde GJC, Spiller DG, Kennedy SM, Ray DW, Sullivan E, et al.: NFκB signaling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 2003;116:2495-2503.
28. Heck S, Bender K, Kullmann M, Göttlicher M, Herrlich P, Cato ACB: IκBα-independent downregulation of NF-κB activity by glucorcorticoid receptor. EMBO J 1997;16: 4698-4707.
29. Cunningham SC, Ryu B, Sohn TA, Kern SE: Nonspecific enhancement of gene expression by compounds identified in high-throughput cell-based screening. Biotechniques 2004;37:120-122.